Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Non-Current Assets (2019 - 2025)

Benitec Biopharma has reported Non-Current Assets over the past 7 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $1.1 million for Q4 2025, down 98.63% from a year ago — trailing twelve months through Dec 2025 was $4.3 million (down 94.66% YoY), and the annual figure for FY2025 was $1.1 million, up 100.37%.
  • Non-Current Assets reached $1.1 million in Q4 2025 per BNTC's latest filing, up from $948000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $79.1 million in Q4 2024 and bottomed at $439000.0 in Q3 2024.
  • Median Non-Current Assets over the past 5 years was $984500.0 (2021), compared with a mean of $4.8 million.
  • The largest annual shift saw Non-Current Assets skyrocketed 14095.33% in 2024 before it crashed 98.63% in 2025.
  • Over 5 years, Non-Current Assets stood at $1.3 million in 2021, then plummeted by 30.7% to $930000.0 in 2022, then tumbled by 40.11% to $557000.0 in 2023, then surged by 14095.33% to $79.1 million in 2024, then plummeted by 98.63% to $1.1 million in 2025.
  • Business Quant data shows Non-Current Assets for BNTC at $1.1 million in Q4 2025, $948000.0 in Q3 2025, and $1.1 million in Q2 2025.